Zymeworks initiated with a Buy at TD Cowen on Ziihera's opportunities

6 hours ago 1

Zymeworks (NASDAQ:ZYME) has been initiated with a Buy rating at TD Cowen, citing the company’s differentiated technology platforms, promising clinical pipeline, and strong financial positioning.
Analysts at TD Cowen believe that Zymeworks' partnership with Jazz Pharmaceuticals (JAZZ) and Beigene

Recommended For You